Predictive power of quasimesenchymal phenotype in epithelial malignancies https://doi.org/10.1038/s41379-018-0196-2
Mahadevan et al. used RNA in situ hybridization probes for epithelial-mesenchymal transition-related genes expressed in circulating tumor cells to assess the role of this transition in metastasis. Using a panel of 158 pancreatic ductal adenocarcinomas and 205 colonic adenocarcinomas, the group assessed expression of their RNA probes, using SMAD4 expression as a biomarker. They developed an expression signature that signified epithelial phenotypes and a second that signified quasimesenchymal phenotypes and showed that the quasimesenchymal phenotype, in both pancreatic and colonic adenocarcinoma samples, correlated with significantly shorter disease-specific and metastasis-free survival. SMAD4 loss demonstrated the same thing, but proved to be a less robust predictor of metastases. Chemotherapy-naïve epithelial tumors showed a superior metastasis-free survival when compared to chemotherapynaïve quasimesenchymal tumors. This could allow predictive modeling in clinical care and better assessment for clinical trial entry to better target current therapeutic strategies.
T-cell infiltration in DLBCL patients
https://doi.org/10.1038/s41379-018-0193-5
Anti-PD-1/PD-L1 immunotherapy is now a cornerstone in oncology; however, the prognostic significance of PD-1/ Mice lacking the ubiquitin ligase RNF5 were shown to exhibit attenuated activation of the unfolded protein response (UPR) components, which has downstream effects on inflammasome, recruitment of dendritic cells and expression of antimicrobial peptides in intestinal epithelial cells. Curiously, reduced UPR expression is also seen in both mouse and human melanoma specimens that responded to immune checkpoint therapy. A subset of 11 bacterial strains were identified as being enriched in Rnf5 −/− mice. These specific bacteria, when introduced orally to germ-free WT mice, conferred a previously unseen antitumor immunity and restricted melanoma growth through increased expression of Toll-like receptors. This study identifies an unexpected relationship between the UPR and gut microbiome and opens doors for further analysis of the relationship between the UPR, gut microbiota and immune checkpoint activity in the clinic.
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Manipulation of gut microbiome in metabolic diseases
Data are accumulating that link the human gut microbiome to immune function and metabolic disease, including type 2 diabetes and obesity. Sanna et al. show a causal effect of butyrate-producing activity of the gut following a glucose-tolerance test, with specific bacteria increasing in abundance in sharp correlation with butyrate abundance. Using bidirectional Mendelian randomization on a normoglycemic patient group, 17 traits were identified to increase fecal propionate levels and to be causally associated with an increase in body mass index. Larger sample sizes will be required to fully assess microbiome features and better understand the interplay between the gut microbiome and host metabolism. This group explored whether manipulation of the gut microbiome might offer an alternative to pharmacological interventions. Should such manipulation be demonstrated to lead to clinical benefit, it could represent an important avenue of intervention in common metabolic diseases.
Nature Genetics 2019;51:600-605; https://doi.org/10.1038/s41588-019-0350-x Current polygenic risk scores can exacerbate health disparities
The development of polygenic risk scores as a way to predict complex traits based on genetic data is a growing field, but Martin et al. elaborate some complex ethical considerations to be addressed before they can be widely utilized. Historic biases have been seen in European genome-wide association studies, which have far greater sample sizes than those undertaken in other regions. The use of polygenic risk scores in precision medicine would therefore bias benefit towards those of European descent, not because of inferred clinical benefit but because of data availability. The authors illustrate that understudied populations reveal variants that could be common in these groups but rare/absent in European populations and would not, therefore, be visible even with larger European sample sizes. They encourage researchers to seek greater diversity in genetic studies and an open system for public dissemination of data to allow more equitable applications of polygenic risk scores.
